A parasite that does not cause disease but allows immunity
For over two decades, a single researcher's pursuit of a neglected parasite has arrived at a rare threshold: the first vaccine ever designed against leishmaniasis — a disease that disfigures, disables, and quietly spreads — has received FDA clearance to enter human trials. Engineered through CRISPR gene-editing, the vaccine revives an ancient immunization practice with modern precision, offering a potential path to protection for the billion people living in its shadow. What begins as a safety trial in Kenya, Brazil, and possibly Cincinnati carries within it the weight of a disease long dismissed as someone else's problem — and the possibility that it need not remain anyone's problem at all.
- Leishmaniasis infects six million people at any given moment and threatens a billion more across 99 countries, yet until now no vaccine has ever existed to stop it.
- The disease is no longer distant — sand fly habitats are expanding into the United States, turning a 'tropical problem' into a domestic public health concern.
- A CRISPR-disabled parasite that can train the immune system without causing illness has cleared FDA review and is weeks away from its first human test.
- Trials enrolling 75–100 volunteers in endemic regions must first prove safety before the harder question — does it actually work in people — can even be asked.
- A successful vaccine priced under five dollars could displace treatments costing up to $200 requiring weeks of painful injections, removing the economic trap that fuels drug resistance.
- Ten million dollars in international funding and a coalition spanning five continents signal that the world is, at last, paying attention to a disease it long ignored.
For more than twenty years, Ohio State pathologist Abhay Satoskar has pursued a parasite that most of the world has chosen not to see. That pursuit has now reached a milestone almost no academic researcher achieves: FDA clearance to test a leishmaniasis vaccine in human beings — the first of its kind ever to cross that threshold.
The disease spreads through sand fly bites and takes multiple forms. The cutaneous version scars and disfigures skin. The visceral form attacks organs and kills if untreated. Up to a million new cases emerge each year, six million people carry active infections at any moment, and a billion more live in the 99 countries where the parasite thrives — including, increasingly, the United States, as warming climates expand the sand fly's range.
Satoskar's vaccine draws on both ancient practice and cutting-edge science. His team used CRISPR to delete a single structural gene — centrin — from the Leishmania parasite. The modified organism can still enter human cells and briefly replicate, but cannot cause disease. This engineered parasite is then used in the tradition of leishmanization, a centuries-old Middle Eastern practice of deliberate exposure to build immunity. In mice, the approach produced strong protection without harm.
The coming phase 1 trial will enroll 75 to 100 healthy volunteers in Kenya and Brazil, with a possible Cincinnati site added. Safety is the primary question, but blood draws will also measure immune response — including in participants who may have already encountered the parasite naturally, whose reactions could reveal important risks or advantages.
Running alongside the vaccine effort is a companion skin test, modeled on tuberculosis screening, that would reveal past exposure and immunity — a surveillance tool Satoskar considers essential for tracking the disease and measuring the vaccine's real-world impact in communities.
The economic argument for success is difficult to overstate. Current treatment costs $100 to $200 and demands weeks of daily injections with serious side effects — a burden so heavy that many patients quit early, allowing drug resistance to grow. The vaccine would likely cost under five dollars. Beyond money lies the human dimension: disfigurement, disability, stigma, and poverty follow the disease wherever it goes.
Backed by $10 million from the Global Health Innovative Technology Fund and the Wellcome Trust, and partnered with institutions across Japan, Brazil, the U.S., and the UK, the trial carries both the infrastructure and the urgency of a problem the world can no longer afford to defer. The science has held in animals. Now it must hold in people.
For more than two decades, Abhay Satoskar has been chasing a parasite. The Ohio State pathologist and his team have just crossed a threshold that few academic researchers reach: their leishmaniasis vaccine, engineered using CRISPR gene-editing, has cleared FDA approval to begin testing in humans. The trial is expected to launch within months, marking the first vaccine ever designed to protect against a disease that disfigures skin, spreads through sand fly bites, and is quietly gaining ground in the United States.
The numbers tell part of the story. Up to a million new cases of cutaneous leishmaniasis appear each year worldwide. At any given moment, roughly six million people carry active infections. But the true measure of the disease's reach is the billion people across 99 countries and territories—including the U.S.—who live in places where it thrives and remain vulnerable. For decades, leishmaniasis has been a problem of tropical regions, a disease that happened elsewhere. That geography is shifting.
Satoskar's approach is elegant in its simplicity, though the science required to get there was anything but simple. He and his collaborators used CRISPR technology to delete a single gene—centrin—from the Leishmania parasite. This gene normally supports the parasite's physical structure. Without it, the organism can still invade human cells and replicate, but only briefly and never enough to cause actual disease. The team then applied this mutated parasite to an ancient practice: leishmanization, a Middle Eastern tradition dating back centuries in which people were deliberately exposed to live parasites to build immunity. Modern technology refined an old idea. In mice, the approach worked. The animals developed robust protection against the disease without suffering harm.
The FDA's approval of an investigational new drug application last year was the formal gate-opening. "This means the FDA has seen the product and our preclinical data and has deemed that this product can be tested in people now," Satoskar said at the time. The significance extends beyond one vaccine. Once the American regulator endorses a product, other health authorities worldwide take notice. The pathway clears.
The initial human trial will enroll between 75 and 100 healthy volunteers in Kenya and Brazil—two countries where leishmaniasis is endemic and where the vaccine will eventually be deployed. A site in Cincinnati may be added. The focus is safety first, but researchers will also draw blood to measure immune response. Testing in endemic regions matters because some participants may have already encountered the parasite and carry antibodies. The team needs to know whether prior exposure triggers an allergic reaction or other complications.
Parallel to the vaccine work, Satoskar's group is developing a skin test for leishmaniasis, modeled on the tuberculosis skin test. A positive result would indicate both past exposure and immunity—a tool for tracking disease spread and measuring how well the vaccine works in communities. "Without this kind of test, you cannot do surveillance," Satoskar explained. "You cannot know the level of immunity in the community."
If phase 1 succeeds, the team plans a phase 2 trial involving at least 3,000 people to measure effectiveness and side effects. The economic case for a vaccine is stark. Treatment currently costs $100 to $200 in the hardest-hit countries and requires weeks of daily injections with significant side effects—a burden that leads many patients to stop treatment early, allowing parasites to develop drug resistance. A vaccine would likely cost less than five dollars. Beyond economics lies the human toll: leishmaniasis causes disfigurement, disability, social stigma, and poverty. A more severe form, visceral leishmaniasis, attacks organs and kills if untreated. Satoskar's team is also developing a separate vaccine for that parasite using the same CRISPR approach.
The trial is backed by ten million dollars in grants from the Japan-based Global Health Innovative Technology Fund and the Wellcome Trust UK. Partners include universities in Japan and Brazil, the National Institute of Allergy and Infectious Diseases, Johns Hopkins University, and the FDA itself. The infrastructure is in place. The science is proven in animals. Now comes the hardest part: proving it works in people, in the places where it matters most.
Citas Notables
This means the FDA has seen the product and our preclinical data and has deemed that this product can be tested in people now. It's a big milestone in terms of product development, especially when the product was conceived in academia.— Abhay Satoskar, Ohio State University
An effective prophylactic vaccine is indispensable for elimination or eradication of leishmaniasis. This is true for almost all infectious diseases.— Abhay Satoskar
La Conversación del Hearth Otra perspectiva de la historia
Why does a disease that's been around for centuries suddenly need a vaccine now?
It's not sudden—Satoskar's been working on this for twenty years. But the disease is moving. It's spreading into the U.S., into places it wasn't before. And the current treatment is brutal: weeks of injections, side effects that make people quit early, parasites that develop resistance. A vaccine changes the equation entirely.
CRISPR is everywhere now. Why is this particular use of it novel?
Because they didn't just delete a gene and hope. They deleted a gene that weakens the parasite in a very specific way—it can still infect cells, still trigger immunity, but can't cause disease. They took an ancient practice, leishmanization, and made it safe with modern tools. That's the innovation.
Seventy-five to a hundred people in phase 1 seems small.
It is. But they're testing in endemic regions where some people have already been exposed. That's actually harder than testing in a place where no one's seen the parasite. If it's safe there, it's likely safe everywhere.
What happens if phase 1 works?
Phase 2 with thousands of people to measure whether it actually prevents disease. Then, if that works, you have a five-dollar vaccine instead of a hundred-dollar treatment. You change the calculus for a billion people at risk.
The skin test seems almost secondary.
It's not. You can't manage a disease you can't measure. The skin test lets you know who's immune, who's been exposed, whether the vaccine is working in a community. It's surveillance infrastructure.
What's the biggest risk here?
That it works in mice but not in humans. Or that people who've already been exposed have a bad reaction. That's why they're testing in endemic regions first—to find those problems before wider deployment.